Vertex Inc. (VERX)
Vertex On Track To Significantly Improve Revenue And Earnings By 2030
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets.
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.
The company discloses narrower-than-expected access to its new painkiller.
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following their two-day meeting. The Dow Jones Industrial Average, S&P 500, and Nasdaq all fell.
Why Vertex Pharmaceuticals Stock Is Sinking Today
Shares of Vertex Pharmaceuticals (VRTX -11.69%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday.
Rising Costs Weigh on Vertex Q1 Earnings
Here's our initial take on Vertex Pharmaceuticals' (VRTX -0.27%) first-quarter financial report.
Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)
Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journavx look promising. Casgevy's progress is slow but uptake should improve going forward.
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!
Vertex (VERX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Vertex (VERX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Vertex (VERX) Beat Estimates Again in Its Next Earnings Report?
Vertex (VERX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Vertex Pharmaceuticals (VRTX 2.72%) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes.
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX -1.39%) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding into other promising billion-dollar opportunities.
